Biopharma’s Battle for Long-Term Manufacturing Contracts
21 October 2026.Biopharma manufacturers compete for contracts, specialist capabilities and sustainable growth
Biopharma manufacturers compete for contracts, specialist capabilities and sustainable growth
Britain’s Hybrid Navy faces challenges turning autonomous surveillance into capability
mRNA advances raise manufacturing demands, but CDMO returns remain uncertain
DroneX 2026 highlights mounting pressures on drone manufacturing and procurement
CPHI Milan examines what turns pharmaceutical innovation into commercial scale
CPHI Milan tests manufacturing capability, execution, validation and proven performance
CPHI Milan highlights specialist capacity, resilient supply and scalable AI
US defence links autonomy, resilience and procurement in major reforms
Britain reshapes battlefield reconnaissance with AR5 and smaller tactical drones
Clinical trials are getting harder to run as complexity increases
Counter-UAS procurement shifts towards integrated systems, common standards and scale
Small drones are reshaping defence through layered, affordable counter-UAS strategies
Commercial site transfers reshape CDMO growth, revenue timing and value
Faster trials increase demand for flexible, resilient clinical supply networks
Australia’s defence build-up tests industry, supply chains and delivery capacity
US pharma investment shifts toward strategic, complex, domestic manufacturing capacity
Washington expands missile production, but rebuilding depleted inventories takes years
Washington targets critical material dependencies across batteries, bauxite and magnets
Moderna’s flu approval tests whether mRNA can deliver commercial scale
Washington targets missile and drone bottlenecks across critical defence supply chains